Caliber Therapeutics, Inc.
Pioneering a new era in atherosclerotic disease intervention with advanced, minimally-invasive drug delivery solutions for maximum efficacy and safety.
Pioneering a new era in atherosclerotic disease intervention with advanced, minimally-invasive drug delivery solutions for maximum efficacy and safety.
Caliber Therapeutics, Inc. is a pioneering company in the field of atherosclerotic disease intervention, offering advanced, minimally-invasive drug delivery solutions for maximum efficacy and safety. Founded in 2005, the company focuses on developing and bringing to market minimally-invasive balloon-based drug delivery products designed to treat atherosclerotic diseases. Their flagship product, the Targeted Angioplasty Drug Delivery balloon, provides a platform for delivering anti-restenotic drugs without the need for stents. This innovative technology allows for precise and controlled drug administration, reducing the risk of thrombosis and minimizing the necessity for permanent implants.
Caliber Therapeutics operates in the Biotechnology, Health Care, Health and Wellness, and Logistics and Delivery industries. The company received a significant $12.00M Venture Round investment on 13 June 2017 from SternAegis Ventures, showcasing investor confidence in its innovative approach to atherosclerotic disease treatment. With its focus on advanced, minimally-invasive solutions, Caliber Therapeutics, Inc. is well-positioned to make a meaningful impact in the field of interventional cardiology and atherosclerotic disease management.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Venture Round | $12.00M | 1 |
|
13 Jun 2017 |
No recent news or press coverage available for Caliber Therapeutics, Inc..
We care about your data, and we'd love to use cookies make your experience better.
